Published date: 20 August 2024
Awarded contract - This means that the contract has been awarded to a supplier.
Contract summary
Industry
Pharmaceutical products - 33600000
Location of contract
WA7 2ES
Value of contract
£380,950,720
Procurement reference
CF-2545400D0O000000rwimUAA
Published date
20 August 2024
Closing date
5 April 2024
Closing time
1pm
Contract start date
1 September 2024
Contract end date
31 August 2026
Contract type
Supply contract
Procedure type
Open procedure (above threshold)
Any interested supplier may submit a tender in response to an opportunity notice.
This procedure can be used for procurements above the relevant contract value threshold.
Contract is suitable for SMEs?
Yes
Contract is suitable for VCSEs?
No
Description
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024
Offer reference number: CM/PHR/22/5689
CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
More information
Attachments
-
- Transparency Award Schedules - London & South of England - CM_PHR_225689_02.pdf
- Transparency Award Schedules - London & South of England - CM_PHR_225689_02
-
- Transparency Award Schedules - London & South of England - CM_PHR_225689_01.pdf
- Transparency Award Schedules - London & South of England - CM_PHR_225689_01
-
- Transparency Award Schedules - Omalizumab and Diroximel Fumarate for MAE & NOFE - CM_PHR_225689_03.pdf
- Transparency Award Schedules - Omalizumab and Diroximel Fumarate for MAE & NOFE - CM_PHR_225689_03
-
- Parties Appointed to Framework Agreement -CM_PHR_22_5689 - London & South of England - 1st September 2024.doc
- Parties Appointed to Framework Agreement -CM_PHR_22_5689 - London & South of England - 1st September 2024
-
- Framework Agreement and Terms and Conditions - CM_PHR_22_5689 - London & South of England - 1st September 2024.pdf
- Framework Agreement and Terms and Conditions - CM_PHR_22_5689 - London & South of England - 1st September 2024
Award information
Awarded date
22 July 2024
Contract start date
1 September 2024
Contract end date
31 August 2026
Total value of contract
£380,950,720
This contract was awarded to 29 suppliers.
Sun Pharma UK Ltd
Address
6-9 The Square Stockley Park Uxbridge UB11 1FW
Reference
None
Biogen
Address
Biogen Building 5 Foundation Park, Roxborough Way, Maidenhead, Berkshire SL6 3UD
Reference
None
Merck Sharpe & Dohme (UK) Limited
Address
120 Moorgate, London EC2M 6UR
Reference
None
Celltrion Healthcare United Kingdom Limited
Address
The Switch, 1-7 The Grove, Slough, SL1 1QP
Reference
None
AstraZeneca
Address
2 St Pancras Square, Kings Cross, London N1C 4AG
Reference
None
Janssen-Cilag Ltd
Address
50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG
Reference
None
Organon Pharmaceuticals UK Ltd
Address
Hewett Building, Hewett Street, London EC2A 3NP
Reference
None
Thornton and Ross Ltd
Address
The Globe, Slaithwaite, Huddersfield HD7 5JN
Reference
None
GlaxoSmithKline UK Limited
Address
980 Great West Road Brentford Middlesex TW8 9GS
Reference
None
Takeda UK Ltd
Address
1 Kingdom Street London W2 6BD
Reference
None
Pfizer Ltd
Address
Walton Oaks, Dorking Road, Walton-on-the-Hill, Tadworth, Surrey, KT20 7NS
Reference
None
Novartis Pharmaceuticals UK Ltd
Address
2nd Floor, The Westworks Building, White City Place, 195 Wood Lane, London, W12 7FQ
Reference
None
Zentiva Pharma UK Ltd
Address
First Floor, Andrews House, College Road, Guildford, GU1 4QB
Reference
None
Roche Products Ltd
Address
BDOP, Hexagon Place, Falcon Way, Shire Park, Welwyn Garden City AL7 1TW
Reference
None
Eli Lilly & Company Ltd
Address
Lilly House, Basing View, Basingstoke, Hampshire, RG21 4FA
Reference
None
Aventis Pharma ltd t/a Sanofi
Address
410 Thames Valley, Park Drive, Reading, Berkshire RG6 1PT
Reference
None
Accord-UK Ltd
Address
Whiddon Valley Barnstaple Devon EX32 8NS
Reference
None
Orifarm UK
Address
236 Jubilee House, 3 The Drive Great Warley Brentwood Essex CM13 3FR
Reference
None
Galapagos Biotech Ltd
Address
Belmont House, 148 Belmont Road,Uxbridge UB8 1QS
Reference
None
Manx Healthcare Ltd
Address
Unit 2 Bosworth Avenue, Tournament Fields, Warwick, CV34 6UQ
Reference
None
Chugai Pharma UK Ltd
Address
2nd Floor, Mulliner House, Flanders Road, Turnham Green London W4 1NN
Reference
None
Napp Pharmaceuticals Ltd
Address
Unit 198 Cambridge Science Park, Milton Road, Cambridge CB4 0AB
Reference
None
Dr.Reddy's Laboratories (UK) Limited
Address
410, Cambridge Science Park Milton Rd, Milton, Cambridge CB4 0PE
Reference
None
LEO Pharma
Address
Building 5, Foundation Park, Roxborough Way, Maidenhead, Berkshire, SL6 3UD
Reference
None
Gedeon Richter UK Ltd
Address
127 Shirland Rd Maida Vale London W9 2EP
Reference
None
BIOSIMILAR COLLABORATIONS IRELAND LIMITED
Address
16 Great Queen Street, Covent Garden, London, WC2B 5AH
Reference
None
Sobi (Swedish Orphan Biovitrum Ltd)
Address
Suite 2 Riverside 3 Great Abington Cambridgeshire CB21 6AD
Reference
None
Teva UK Limited
Address
Ridings Point, Whistler Drive, Glasshoughton Castleford, WF10 5HX
Reference
None
UCB Pharma Ltd (primary)
Address
208 Bath Road, Slough, Berkshire, SL1 3WE
Reference
None
About the buyer
Contact name
Lynne Tierney
Address
2nd Floor Rutland House
Runcorn
WA7 2ES
GB
Share this notice
Closing: 5 April 2024, 1pm